- Home
- PT vs BLRX Comparison
PT vs BLRX Comparison
Compare PT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PT
- BLRX
- Stock Information
- Founded
- PT 2012
- BLRX 2003
- Country
- PT China
- BLRX Israel
- Employees
- PT N/A
- BLRX N/A
- Industry
- PT Computer Software: Programming Data Processing
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PT Technology
- BLRX Health Care
- Exchange
- PT Nasdaq
- BLRX Nasdaq
- Market Cap
- PT 14.8M
- BLRX 17.3M
- IPO Year
- PT 2018
- BLRX 2011
- Fundamental
- Price
- PT $0.95
- BLRX $3.48
- Analyst Decision
- PT
- BLRX Strong Buy
- Analyst Count
- PT 0
- BLRX 2
- Target Price
- PT N/A
- BLRX $5.50
- AVG Volume (30 Days)
- PT 18.8K
- BLRX 432.3K
- Earning Date
- PT 11-08-2024
- BLRX 03-25-2025
- Dividend Yield
- PT N/A
- BLRX N/A
- EPS Growth
- PT N/A
- BLRX N/A
- EPS
- PT N/A
- BLRX N/A
- Revenue
- PT $4,479,352.00
- BLRX $21,991,000.00
- Revenue This Year
- PT N/A
- BLRX N/A
- Revenue Next Year
- PT N/A
- BLRX N/A
- P/E Ratio
- PT N/A
- BLRX N/A
- Revenue Growth
- PT N/A
- BLRX N/A
- 52 Week Low
- PT $0.71
- BLRX $0.08
- 52 Week High
- PT $1.27
- BLRX $4.44
- Technical
- Relative Strength Index (RSI)
- PT 47.63
- BLRX 92.08
- Support Level
- PT $0.93
- BLRX $3.24
- Resistance Level
- PT $1.01
- BLRX $3.70
- Average True Range (ATR)
- PT 0.07
- BLRX 0.17
- MACD
- PT -0.00
- BLRX 0.41
- Stochastic Oscillator
- PT 73.85
- BLRX 77.98
About PT Pintec Technology Holdings Limited
Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees also by providing financing for these borrowers and earn installment service fees, They earn wealth management services fees and commission on financial products.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.